Organogenesis Holdings (ORGO) Non-Current Assets (2015 - 2026)

Organogenesis Holdings' (ORGO) quarterly Non-Current Assets came in at $251.5 million in Q1 2026, up 26.23% year-on-year from $199.2 million in Q1 2025, and up 6.32% quarter-over-quarter from $236.5 million in Q4 2025.

Organogenesis Holdings (ORGO) Non-Current Assets (2015 - 2026) Analysis & Trends

Organogenesis Holdings' Non-Current Assets history runs 12 years deep, the most recent figure standing at $251.5 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 26.23% year-over-year to $251.5 million in Q1 2026; TTM through Mar 2026 was $899.0 million, a 8.59% increase from a year earlier, with the FY2025 full-year figure at $236.5 million, up 11.61% from the prior year.
  • Non-Current Assets grew to $251.5 million in Q1 2026 per ORGO's latest filing, from $236.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $251.5 million in Q1 2026 and bottomed at $199.2 million in Q1 2025.
  • The 5-year median for Non-Current Assets is $226.7 million (2022), against an average of $223.0 million.
  • Across the five-year window, Non-Current Assets jumped 63.07% in 2022 and fell 13.87% in 2025, its largest moves.
  • Year by year, Non-Current Assets stood at $226.8 million in 2022, then climbed by 3.63% to $235.0 million in 2023, then fell by 9.8% to $211.9 million in 2024, then increased by 11.61% to $236.5 million in 2025, then grew by 6.32% to $251.5 million in 2026.
  • Per Business Quant, the three latest ORGO Non-Current Assets figures stand at $251.5 million (Q1 2026), $236.5 million (Q4 2025), and $210.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 36.78 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 26.33 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 8.68 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 79.20 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 3.84 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 15.70 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 25.92 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 2.47 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 9.64 Bn
10 Organogenesis Holdings 310.55 Mn 218.45 Mn 11.46 Mn 251.49 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 251.49 Mn
Dec 31, 2025 236.54 Mn
Sep 30, 2025 210.08 Mn
Jun 30, 2025 200.91 Mn
Mar 31, 2025 199.23 Mn
Dec 31, 2024 211.95 Mn
Sep 30, 2024 207.79 Mn
Jun 30, 2024 208.97 Mn
Mar 31, 2024 231.31 Mn
Dec 31, 2023 234.98 Mn
Sep 30, 2023 237.07 Mn
Jun 30, 2023 233.88 Mn
Mar 31, 2023 229.29 Mn
Dec 31, 2022 226.75 Mn
Sep 30, 2022 226.75 Mn
Jun 30, 2022 224.81 Mn
Mar 31, 2022 218.42 Mn
Dec 31, 2021 216.28 Mn
Sep 30, 2021 158.59 Mn
Jun 30, 2021 153.80 Mn